Clinical Trial

Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

Study acronym: FOLFIRINOX3 P
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Evaluate the efficacy of treatment FOLFORINOX 3 in first-line therapy for patients with locally advanced unresectable or metastatic pancreatic cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-09.
Status change: Not Yet Recruiting → Recruiting 2024-02-09
Trial Details
NCT Number NCT05988814
Lead Sponsor Centre Georges Francois Leclerc
Conditions Metastatic Pancreatic Cancer
Enrollment 90 participants
Start Date 2024-01-24
Primary Completion 2029-07-24 (estimated)
Study Completion 2029-07-24 (estimated)
Updated on ClinicalTrials.gov 2024-02-12